CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE
+0.16 (+3.40%)4.72USD1.7M成交股數2.6B市值–本益比(近四季)1.0股價營收比+55.6%營收年增(近四季)2026-11-04下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 743M+56% | 749M+62% | 488M+47% | 497M+39% | 478M+38% | 462M+48% | 331M+8% | 356M+11% | 347M | 312M | 306M | 320M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | 81.2M+16% | 108M+42% | 81.8M | 64.0M | 70.2M | 75.9M |
| 毛利率 | – | – | – | – | – | – | 24.5% | 30.3% | 23.6% | 20.5% | 23.0% | 23.7% |
| 研發費用 | – | – | – | – | – | – | – | – | – | – | – | – |
| 銷售管理費用 | 70.3M | 74.6M | 66.2M | 49.0M | 48.5M | 50.7M | 35.2M | 44.4M | 44.6M | 42.7M | 41.0M | 41.7M |
| 營業利益 | 28.0M-365% | 27.3M-2246% | −49.3M+461% | −24.4M-439% | −10.6M-53% | −1.3M-98% | −8.8M-74% | 7.2M-125% | −22.7M | −63.1M | −33.6M | −28.9M |
| 營業利益率 | 3.8% | 3.6% | -10.1% | -4.9% | -2.2% | -0.3% | -2.7% | 2.0% | -6.5% | -20.2% | -11.0% | -9.0% |
| 稅後淨利 | 28.0M-365% | 27.3M-2246% | −49.3M+439% | −24.4M-429% | −10.6M-45% | −1.3M-98% | −9.2M-78% | 7.4M-126% | −19.2M | −70.5M | −41.5M | −28.8M |
| 淨利率 | 3.8% | 3.6% | -10.1% | -4.9% | -2.2% | -0.3% | -2.8% | 2.1% | -5.5% | -22.6% | -13.6% | -9.0% |
| 稀釋 EPS | 0.05-350% | 0.05 | – | – | -0.02 | 0.00-100% | – | – | – | -0.14 | -0.09 | -0.06 |
| 稀釋股數 | 545M | 533M | 512M | 513M | 509M | 497M | 490M | 495M | 486M | 482M | 481M | 479M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 199M | 173M | 78.3M | 190M | 189M | 155M | 288M | 255M | 208M | 123M | 299M | 310M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 720M | 698M | 541M | 560M | 575M | 584M | 653M | 674M | 672M | 571M | 685M | 702M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 344M | 358M | 232M | 219M | 231M | 248M | 311M | 349M | 379M | 284M | 738M | 927M |
| 股東權益 | 376M | 339M | 309M | 341M | 344M | 336M | 342M | 325M | 292M | 286M | 322M | 331M |
| 負債比 | 47.8% | 51.4% | 42.9% | 39.1% | 40.1% | 42.4% | 47.6% | 51.8% | 56.5% | 49.8% | 107.7% | 132.1% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 108M-762% | – | – | – | −16.3M | – | – | 25.9M | – | – | – |
| 資本支出 | – | 854K | – | – | – | 185K | – | – | 445K | – | – | – |
| 自由現金流 | – | 107M-750% | – | – | – | −16.5M | – | – | 25.5M | – | – | – |
| 折舊攤銷 | 564K | −441K | −2.2M | 406K | 394K | −437K | 339K | 330K | −671K | −2.3M | 557K | 999K |
| 買回庫藏股 | – | 0 | – | – | – | 18.3M | – | – | 0 | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 14.3% | – | – | – | -3.6% | – | – | 7.3% | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 1.9B | +40.3% | −85.5M | -4.4% | – | −69.0M |
| FY2024 | 1.4B | +8.8% | −43.0M | -3.1% | – | 33.3M |
| FY2023 | 1.3B | +15.0% | −213M | -16.9% | -0.44 | −145M |
| FY2022 | 1.1B | -25.5% | −339M | -30.9% | -0.71 | −208M |
| FY2021 | 1.5B | +118.8% | −588M | -39.9% | -1.42 | −283M |
| FY2020 | 673M | +45.6% | −136M | -20.3% | -1.54 | −119M |
| FY2019 | 462M | – | −364M | -78.7% | -4.14 | −160M |